| First Author | Connelly CD | Year | 1994 |
| Journal | Life Sci | Volume | 54 |
| Issue | 21 | Pages | PL369-74 |
| PubMed ID | 7910928 | Mgi Jnum | J:19590 |
| Mgi Id | MGI:67708 | Doi | 10.1016/0024-3205(94)90037-x |
| Citation | Connelly CD, et al. (1994) Etonitazene-induced antinociception in mu1 opioid receptor deficient CXBK mice: evidence for a role for mu2 receptors in supraspinal antinociception. Life Sci 54(21):PL369-74 |
| abstractText | The prevailing view is that supraspinal mu opioid-mediated antinociception in mice is mediated via the mu 1 subtype. The purpose of the present study was to determine if the highly mu-selective compound etonitazene could produce supraspinal (intracerebroventricular; i.c.v.) antinociception in CXBK mice, which are deficient in brain mu1, but not mu2, opioid receptors. CXBK or normal Crl:CD-1 (ICR)BR mice were administered graded doses of etonitazene i.c.v. and 15 min later antinociception was assessed by a standard radiant-heat or 55 degrees C water tail-flick test. Etonitazene produced dose-related antinociception that was blocked by naloxone and by beta-FNA (demonstrating a mu opioid mechanism), but not by either ICI-174,864 or naltrindole (demonstrating the lack of involvement of delta opioid receptors). These findings suggest that mu2 opioid receptors are important contributors to opioid-induced supraspinal antinociception in mice. |
